PÃ¥l Andre Holme

List of Publications by Year
in descending order

60 papers	2,436 citations	430874 18 h-index	206112 48 g-index
62 all docs	62 docs citations	62 times ranked	3947 citing authors

#	Article	IF	Citations
1	Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 384, 2124-2130.	27.0	1,155
2	Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematology,the, 2016, 3, e64-e71.	4.6	311
3	Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 1653-1661.	13.7	167
4	Evaluation of the utility of the <scp>ISTH</scp>â€<scp>BAT</scp> in haemophilia carriers: a multinational study. Haemophilia, 2016, 22, 912-918.	2.1	60
5	Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology, 2016, 55, 1337-1339.	1.9	49
6	Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. European Heart Journal, 2021, 42, 4064-4072.	2.2	49
7	Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB Journal, 1998, 12, 79-89.	0.5	41
8	Haemophilic arthropathy: Long-term outcomes in 107 primary total knee arthroplasties. Knee, 2014, 21, 147-150.	1.6	40
9	Hypertension, haematuria and renal functioning in haemophilia â€“ a crossâ€sectional study in Europe. Haemophilia, 2016, 22, 248-255.	2.1	39
10	The Difference Between Platelet and Plasma FXIII Used to Study the Mechanism of Platelet Microvesicle Formation. Thrombosis and Haemostasis, 1993, 70, 681-686.	3.4	38
11	Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10â€year survey. Haemophilia, 2015, 21, 589-597.	2.1	38
12	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thrombosis Journal, 2017, 15, 6.	2.1	32
13	Onceâ€weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8â€GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia, 2019, 25, 373-381.	2.1	29
14	Thrombosis and thrombocytopenia after HPV vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 700-704.	3.8	29
15	rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemophilia, 2011, 17, 764-770.	2.1	23
16	BAY 94â€9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia, 2019, 25, 1011-1019.	2.1	23
17	Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B â€“ The MoHem study. Haemophilia, 2020, 26, 891-897.	2.1	23
18	STIM1 R304W causes muscle degeneration and impaired platelet activation in mice. Cell Calcium, 2018, 76, 87-100.	2.4	21

#	Article	IF	Citations
19	Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia, 2021, 27, 519-530.	2.1	20
20	Home treatment with bypassing products in inhibitor patients: a 7.5â€year experience. Haemophilia, 2009, 15, 727-732.	2.1	17
21	Fixed doses of N8â€GP prophylaxis maintain moderateâ€toâ€mild factor VIII levels in the majority of patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 542-554.	2.3	17
22	Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia, 2018, 24, 24-32.	2.1	15
23	Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series. Journal of Medical Case Reports, 2018, 12, 138.	0.8	15
24	Management of comorbidities in haemophilia. Haemophilia, 2021, 27, 37-45.	2.1	14
25	The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine (United States), 2018, 97, e12551.	1.0	12
26	Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study. Haemophilia, 2019, 25, 334-342.	2.1	12
27	Confirmed longâ€term safety and efficacy of prophylactic treatment with BAY 94â€“9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia, 2021, 27, e347-e356.	2.1	12
28	The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register. Haemophilia, 2017, 23, e180-e187.	2.1	11
29	Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemophilia, 2021, 27, e253-e259.	2.1	10
30	How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population. Haemophilia, 2016, 22, e406-16.	2.1	9
31	Longâ€term outcomes of patients treated with rituximab as secondâ€line treatment for adult immune thrombocytopenia â€“ Followâ€up of the RITP study. British Journal of Haematology, 2020, 191, 460-465.	2.5	9
32	The effect of emicizumab and bypassing agents in patients with hemophilia â€“ An in vitro study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12561.	2.3	8
33	Hematuria in aging men with hemophilia: Association with factor prophylaxis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 309-317.	2.3	7
34	Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets, 2022, 33, 640-644.	2.3	7
35	Immune tolerance induction in the era of emicizumab â€“ still the first choice for patients with haemophilia A and inhibitors?. Haemophilia, 2022, 28, 215-222.	2.1	7
36	Surgical outcomes in patients with haemophilia A or B receiving extended halfâ€life recombinant factor VIII and IX Fc fusion proteins: Realâ€world experience in the Nordic countries. Haemophilia, 2022, 28, 713-719.	2.1	7

#	Article	IF	Citations
37	Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension. Medicine (United States), 2020, 99, e19339.	1.0	6
38	Treatment outcomes in persons with severe haemophilia B in the Nordic region: The Bâ€NORD study. Haemophilia, 2021, 27, 366-374.	2.1	6
39	Comparison of freeâ€living physical activity measurements between ActiGraph GT3Xâ€BT and Fitbit Charge 3 in young people with haemophilia. Haemophilia, 2022, 28, .	2.1	6
40	Platelet function testing: Current practice among clinical centres in Northern Europe. Haemophilia, 2022, 28, 642-648.	2.1	5
41	Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries. Haemophilia, 2019, 25, 54-59.	2.1	4
42	Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency. Hematology, 2020, 25, 17-25.	1.5	4
43	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. Platelets, 2020, 31, 43-47.	2.3	3
44	Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study. Blood, 2018, 132, 2492-2492.	1.4	3
45	Rituximab As Second Line Treatment For Adult Immune Thrombocytopenia (ITP): A Multicentre, Randomized, Double Blind, Placebo-Controlled Study â€“ The Ritp Study (NCT00344149). Blood, 2013, 122, 449-449.	1.4	3
46	The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials. Blood, 2019, 134, 4892-4892.	1.4	3
47	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). Blood, 2021, 138, 2088-2088.	1.4	3
48	Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitorsâ€”An In Vitro Study. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110211.	1.7	2
49	Bone mineral density in haemophilia â€“ a multicentre study evaluating the impact of different replacement regimens. Haemophilia, 2022, 28, 239-246.	2.1	2
50	Clinical outcome and adherence rate in Scandinavian patients with intermediateâ€intensity prophylaxis before and after the switch of standard halfâ€life FVIII products to BAY 81â€“8973. Haemophilia, 2022, 28, 223-229.	2.1	2
51	The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis. Thrombosis Research, 2019, 177, 154-156.	1.7	1
52	Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. Haemophilia, 2021, 27, 793-801.	2.1	1
53	Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO). Blood, 2019, 134, 2418-2418.	1.4	1
54	Renal Status and Hematuria in Older Patients with Hemophilia. Blood, 2015, 126, 2290-2290.	1.4	1

#	Article	IF	Citations
55	Multicentric Study Evaluating Venous Thrombosis Among Patients with Haemophilia Undergoing Major Orthopaedic Surgery. Blood, 2014, 124, 1496-1496.	1.4	1
56	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. Thrombosis and Haemostasis, 2021, , .	3.4	0
57	Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls. Blood, 2016, 128, 875-875.	1.4	0
58	Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (FeibaR) in Patients with Inhibitors. First Demographic Data. Blood, 2016, 128, 5038-5038.	1.4	0
59	Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study. Blood, 2019, 134, 2358-2358.	1.4	0
60	Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO). Blood, 2020, 136, 23-24.	1.4	0